Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer

Next Previous
Search
Trial Profile

A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Modi-1 (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Ovarian cancer; Peritoneal cancer; Pharyngeal neoplasms; Renal cell carcinoma; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Acronyms ModiFY
  • Sponsors Scancell

    • Most Recent Events

    • 30 Jan 2025 According to a Scancell media release, Early clinical data in RCC with Modi-1 plus CPIs is anticipated in H2 2025.
    • 09 Jan 2025 Results presented in a Scancell Media Release.
    • 30 Jan 2024 According to a Scancell media release, Modi-1 to be assessed in renal cell carcinoma in combination with double CPI therapy in the ModiFY study pending protocol amendment by the MHRA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top